From 2012.igem.org

Revision as of 11:52, 19 September 2012

• Home
• Team
  • The Team
  • Team Registration
• Project
  • 1. Introduction
  • 2. PnA System
  • 3. Virus-Like Particles
    • CCMV
    • HepB
    • Polerovirus Natural BioBrick
  • 4. Outside Modification
  • 5. Inside Modification
  • 6. Detection of VLPs
  • 7. Applications
  • 8. The Constructor
  • 9. Final Overview
• Human Practices
  • Human Practices Home
  • 1. Mini Symposium
  • 2. Visiting Secondary Schools
  • 3. Discovery Festival
    • Communication Science
  • 4. Stakeholders
  • 5. Munich CAS Conference
• Safety
  • Introduction
  • 1. General safety
  • 2. Virus-related safety
  • 3. Regulations
  • 4. Safety suggestions
  • 5. Safety of applications
• Modeling
  • Human Body Model
  • Tertiary folding prediction
  • VLP assembly model
• Attributions
• Parts
• Notebook
  • Journal
  • Protocols

---

Last year's project: Synchronized Oscillatory System

iGEM Home

Contact Us

Our Sponsors:

Hepatitis B and the Hepatitis B core Antigen VLP

Introduction

The hepatitis B virus is a widespread virus causing liver infection. About 1% of the population in Western-Europe and Northern America is infected, and up to 5% in less developed countries (http://www.who.int/mediacentre/factsheets/fs204/en/). The virus can be spread by blood-to-blood contact or as std. This is the reason why we do not use full viruses, but the empty shells only. This prevents the transmission.

fig. 1 Map of the prevelance of Hepatitis B

The VLP

The empty shell, or Virus-Like Particle, is formed by the Hepatitis B core Antigen (HepBcAg). The VLP has already been used for the vaccination against Hepatitis B itself, back in 1980 (http://www.sciencedirect.com/science/article/pii/S0034528811004437, Virus-like particles: potential veterinary vaccine immunogens ) Afterwards, the Hepatitis B VLP has been modified and suggested to be used as carrier for epitopes of other pathogens. In this project, we will try to make the attachments of epitopes or ligands even more convenient. The external loop of the Hepatitis B core antigen can be modified, attaching the k-coil to the VLP. Using the PnA System, a wide variety of antigens and ligands can be attached. The inside of the VLP can be modified in a similar way, allowing controlled packaging of proteins inside the VLP.

fig. 1 Map of the prevelance of Hepatitis B